Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended ...

CEO Anne Wojcicki has said she intends to take the company private and is not considering third-party takeover proposals.

The company ... medicine test as the first of its kind to offer simultaneous whole exome sequencing and whole transcriptome ...

Jessica Ko saw others sharing their DNA results online and decided to take a test. The results have changed how she sees ...

No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...

A judge is hearing testimony on the cutting-edge technology that analyzed DNA evidence against Paul Caneiro in the murders of ...

A decade-long effort has resulted in a new, rapid genomic test to diagnose rare infectious diseases in the brain and lungs.

A diagnostic test developed by researchers at the University of California San Francisco aims to help physicians identify causes of severe infections by analyzing DNA and RNA to detect a range of ...

An innovative collaboration with global software testing company Inspired Testing and the software quality ... within the ...

Researchers at University of California San Francisco (UCSF) have developed a single genomic test that can quickly detect ...

Hera Biotech is developing a less invasive, more accurate diagnostic test for endometriosis, an often painful condition that ...